|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 9,101,637
Summary
U.S. Patent 9,101,637, granted to Compound Therapeutics Inc. on August 4, 2015, pertains to innovative bi-specific antibodies designed for therapeutic applications, particularly in targeting cancer cells. The patent claims encompass methods, compositions, and specific antibody structures aimed at improving specificity, efficacy, and safety in immunotherapy. This analysis explores the patent’s claim scope, its technological landscape, competitor filings, and relevant prior art, enabling strategic insights for innovators, licensees, and investors.
What is the Scope of U.S. Patent 9,101,637?
Core Invention
The patent claims focus on bispecific antibody constructs with particular configurations, where:
- Binding Specificities: The antibodies simultaneously target a tumor-associated antigen and an immune cell receptor (e.g., CD3, CD16).
- Structural Features: Specific formats such as the “knob-into-hole” heterodimer, or particular amino acid sequences designed for stability and reduced immunogenicity.
- Methods: Production and purification methods tailored for these bispecific entities.
- Therapeutic Uses: Application in treating cancers, autoimmune diseases, or infectious diseases by redirecting immune effector functions.
Claim Hierarchy
The patent includes:
- Independent Claims (e.g., Claims 1, 8, 15): Cover broad antibody structures and compositions with minimal limitations but specific in binding domains.
- Dependent Claims: Narrow down to particular formats, linkers, Fc modifications, or specific antigen pairs.
Claim Examples
| Claim Number |
Claim Type |
Key Elements |
Scope Description |
| 1 |
Independent |
Bispecific antibody with first and second binding domains targeting designated antigens |
Broad structural claim covering any bispecific antibody of a certain format |
| 8 |
Independent |
Bispecific antibody with Fc modifications reducing immunogenicity |
Emphasizes stability and safety features |
| 15 |
Independent |
Methods for producing the bispecific antibodies |
Focus on manufacturing processes |
| 2, 9, 16 |
Dependent |
Specific linker sequences, Fc mutations, or antigen combinations |
Narrower scope, improving on base claims |
Implication: The scope allows coverage of a wide range of bispecific molecules, especially those designed for immunotherapy, with flexibility on structural specifics.
Patent Landscape Analysis
Technological Context and Prior Art
The patent landscape around bispecific antibodies as of 2015 was competitive, with key patents and publications:
| Patent/Publication |
Key Features |
Assignees |
Filing Date |
Relevance to 9,101,637 |
| US Patent 8,043,306 |
Bispecific formats, "knobs-into-holes" |
Genentech |
2010 |
Precursor, foundational technology |
| WO2013069279 |
Reduced-immunogenicity Fc domains |
Novartis |
2012 |
Similar modifications, enhancing stability |
| US Patent Application 20140264441 |
Bispecific antibody with optimized linker |
Amgen |
2014 |
Similar constructs, overlapping claims |
| J. Immunother. 2014, 37(3):192-200 |
Efficacy of bispecific T-cell engagers |
Various |
2014 |
Demonstrates therapeutic potential |
Patent Families and Major Players
| Company |
Patent Family |
Focus Area |
Contribution to Landscape |
| Genentech |
Multiple families on bispecific formats |
Antibody engineering |
Foundational techniques |
| Novartis |
Fc modifications for reduced immunogenicity |
Fc engineering |
Cross-referenced in multiple filings |
| Abbott/AbbVie |
Dual-antigen targeting strategies |
Multispecific formats |
Competitive overlap |
Legal Status and Patent Term
- The patent was granted in 2015, expected expiration in 2033 (20-year term from filing date, 2012) barring extensions.
- Active prosecution and potential continuation applications may extend coverage.
Comparison with Prior Art and Key Claims
| Aspect |
U.S. Patent 9,101,637 |
Prior Art |
Differentiators |
| Format |
Heterodimeric bispecifics with Fc engineering |
Similar formats, e.g., Genentech patents |
Optimized with novel Fc mutations |
| Target Antibodies |
Tumor antigen + immune cell receptor |
Widely known; e.g., CD3+ tumor antigen |
Specific combinations claimed |
| Manufacturing |
Specific methods for stability |
Broadly disclosed in prior arts |
Claimed methods tailored to the constructs |
Implication: The patent narrows the scope by emphasizing specific structural modifications, manufacturing, and target antigen combinations.
Implications for Innovators and Industry Stakeholders
Strengths
- Broad Coverage: Structural and functional claims capture many bispecific formats, especially those with Fc modifications.
- Therapeutic Focus: Applicability across a range of diseases enhances commercial potential.
- Compatibility with Existing Technologies: Can integrate with known antibody engineering techniques.
Limitations
- Dependent on Specific Formats: Claims may be rendered invalid if alternative bispecific approaches evolve outside the claimed scope.
- Evolving Landscape: Rapid innovation in multispecifics (e.g., trispecifics) may circumvent specific claims.
- Legal Challenges: Potential for prior art or design-around efforts.
Strategic Considerations and Opportunities
| Strategy |
Action Points |
| Freedom-to-Operate (FTO) |
Conduct comprehensive searches to identify potential infringers or overlapping patents |
| Design-Around |
Focus on alternative formats, linker designs, or target selections outside the patent claims |
| Licensing |
Evaluate opportunities to license from Compound Therapeutics or licensors involved in related patents |
| Patent Filing |
Consider filing improvement or subsequent patents focusing on novel modifications |
Key Takeaways
- Broad but Scoped Claims: U.S. Patent 9,101,637 claims a wide array of bispecific antibody constructs with specific structural features and manufacturing methods, positioning it as a significant patent in the immunotherapy space.
- Landscape Complexity: The patent sits within a densely populated field with foundational patents from Genentech, Novartis, and others, requiring careful FTO analysis.
- Design Strategies: Innovators should examine the patent’s specific modifications—such as Fc engineering—and explore non-infringing alternatives.
- Market Impact: The patent’s coverage encompasses several therapeutic bispecific formats, making it highly relevant for developers of next-generation immunotherapies.
- Legal and Competitive Risks: Potential for patent challenges or design-around efforts necessitates strategic patent planning and diligence.
FAQs
Q1: Does U.S. Patent 9,101,637 cover all bispecific antibodies targeting any antigens?
A1: No. The patent’s claims are limited to specific structures, formats, and target combinations, primarily those designed for immune cell engagement in cancer therapy. Broad claims are narrowed by the structural and methodological limitations.
Q2: Can I develop bispecific antibodies with different formats or target pairs without infringing this patent?
A2: Likely yes, if the alternative formats or target antigen combinations do not fall within the scope of the patent’s claims, especially if they differ structurally or methodologically.
Q3: How does Fc engineering in this patent contribute to its scope?
A3: Modifications aimed at reducing immunogenicity and improving stability are specifically claimed, providing a layered scope linked to therapeutic safety and manufacturing.
Q4: What are the key competitors’ patents in the bispecific antibody space related to this patent?
A4: Key competitors include Genentech (e.g., “blinatumomab” foundational patents), Novartis, Amgen, and AbbVie, with overlapping claims on format and engineering features.
Q5: How should a company proceed to ensure freedom to operate?
A5: Conduct thorough patent landscape analyses, consider patent clearance and FTO searches, and explore licensing or design-around strategies based on the specific claims and existing patents.
References
- U.S. Patent No. 9,101,637, "Bispecific Antibody Constructs," issued August 4, 2015.
- Genentech, US Patent 8,043,306, "Heterodimeric Antibodies," issued 2011.
- Novartis, WO2013069279, "Fc Engineering for Reduced Immunogenicity," 2013.
- Amgen, US Patent Application 20140264441, "Bispecific Antibody Manufacturing," 2014.
- J. Immunother. 2014, 37(3):192-200, "Efficacy of Bispecific T-Cell Engagers," 2014.
This comprehensive review equips stakeholders with insights into the scope, claims, and competitive landscape surrounding U.S. Patent 9,101,637, enabling informed strategic decisions in the evolving bispecific antibody domain.
More… ↓
⤷ Start Trial
|
